newsfilter
← Latest News
GlobeNewswire·

Geron Announces Appointment of Chinmaya Rath as Chief Business Officer

  • Geron Corporation appointed Chinmaya Rath as its new Chief Business Officer on July 13, 2026.
  • Rath brings over 25 years of biopharma leadership experience, including significant roles at Novartis, Cellworks, GlycoMimetics, CelluRx, Omega Therapeutics, Social Impact Capital, Catena Biosciences, Menten AI, \& various board positions.
  • His career includes leading enterprise-wide strategic initiatives, integrations of GSK Oncology \& Alcon, \& major U.S. launches for hematology \& solid tumor products.
  • CEO Harout Semerjian stated the appointment aims to maximize RYTELO value globally \& evaluate innovation opportunities.
  • Geron's RYTELO (imetelstat) is approved in the U.S. \& EU for lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
  • The company is conducting a Phase 3 trial for imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis \& studies in other hematologic malignancies.
  • Rath holds MBAs from Warwick Business School \& Army Institute of Management, along with an undergraduate degree in Life Science from Ravenshaw University.
  • The press release includes standard forward-looking statements regarding commercial strategy, regulatory approvals, \& potential risks to RYTELO development \& commercialization.